Beacon Financial Advisory LLC Increases Stock Position in Eli Lilly and Company $LLY

Beacon Financial Advisory LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 16.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 435 shares of the company’s stock after buying an additional 63 shares during the period. Beacon Financial Advisory LLC’s holdings in Eli Lilly and Company were worth $339,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. IVC Wealth Advisors LLC grew its position in Eli Lilly and Company by 2.0% during the second quarter. IVC Wealth Advisors LLC now owns 1,463 shares of the company’s stock valued at $1,140,000 after acquiring an additional 29 shares during the period. Marietta Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 2.1% in the 2nd quarter. Marietta Wealth Management LLC now owns 13,503 shares of the company’s stock valued at $10,526,000 after purchasing an additional 275 shares in the last quarter. Simplicity Wealth LLC grew its holdings in shares of Eli Lilly and Company by 125.2% during the 2nd quarter. Simplicity Wealth LLC now owns 12,288 shares of the company’s stock worth $9,580,000 after purchasing an additional 6,832 shares during the period. OLD National Bancorp IN increased its position in Eli Lilly and Company by 3.0% during the 2nd quarter. OLD National Bancorp IN now owns 628,940 shares of the company’s stock worth $490,278,000 after purchasing an additional 18,365 shares in the last quarter. Finally, Carolina Wealth Advisors LLC increased its position in Eli Lilly and Company by 40.0% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 1,312 shares of the company’s stock worth $1,023,000 after purchasing an additional 375 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.5%

Shares of NYSE:LLY opened at $840.46 on Monday. The firm has a market cap of $795.46 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a fifty day simple moving average of $734.60 and a 200 day simple moving average of $765.44. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period last year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jamere Jackson acquired 200 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have issued reports on LLY. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Guggenheim decreased their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. JPMorgan Chase & Co. cut their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $938.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.